Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-cur (also referred to as Nano-CUR) is a nanoparticle formulation of curcumin encapsulated within poly(lactic acid-co-glycolic acid) (PLGA) polymers. Developed to overcome the poor aqueous solubility, rapid metabolism, and low systemic bioavailability of native curcumin, this formulation utilizes a modified nano-precipitation method to achieve a particle size of approximately 70 nm. Curcumin is a natural polyphenol that exerts anti-cancer effects by modulating multiple signaling pathways. Nano-cur has been shown to downregulate pro-survival proteins such as Bcl-XL and Mcl-1, inhibit the β-catenin signaling pathway, and reduce the expression of HPV E6 and E7 oncogenes. In preclinical models of ovarian and cervical cancer, Nano-cur enhances the sensitivity of tumor cells to cisplatin and radiation therapy and induces apoptosis, suggesting its potential as a therapeutic or sensitizing agent in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nano-curcumin.